Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan

BMC Gastroenterology

Kazuhiko Koike²  Toru Mitsushima¹  Hiroshi Yotsuyanagi²  Kyoji Moriya²  Mitsuhiro Fujishiro²  Shinya Kodashima²  Satoshi Ono²  Yoshiki Sakaguchi²  Yoshizumi Shintani²  Takeya Tsutsumi²  Hidetaka Fujinaga²  Kenichiro Enooku²  Takeshi Shimamoto¹  Nobutake Yamamichi²  Yu Takahashi²  Kazuya Okushin² 

[1] Kameda Medical Center Makuhari (CD-2, 1–3, Nakase, Mihama-ku, Chiba-city, Japan;Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

关键词: Helicobacter pylori;    Metabolic syndrome;    NAFLD;    Fatty liver disease;   

Others  :  1144757
DOI  :  10.1186/s12876-015-0247-9

 received in 2015-01-19, accepted in 2015-02-02,  发布年份 2015

【 摘 要 】

Background

Fatty liver disease (FLD) including non-alcoholic fatty liver disease (NAFLD), a rapidly emerging and widely recognized liver disease today, is regarded as a hepatic manifestation of metabolic syndrome. Helicobacter pylori, one of the most common pathogens worldwide, has been reported to be associated with metabolic syndrome, but whether there is a direct association with FLD is as of yet unclear. The aim of this study was to clarify the association of FLD and NAFLD with causative background factors including Helicobacter pylori infection.

Methods

This was a cross-sectional study of Japanese adults who received medical checkups at a single medical center in 2010.Univariate and multivariate statistical analysis was performed to evaluate background factors for ultrasonography diagnosed FLD. Subjects free from alcohol influence were similarly analyzed for NAFLD.

Results

Of a total of 13,737 subjects, FLD was detected in 1,456 of 6,318 females (23.0 %) and 3,498 of 7,419 males (47.1%). Multivariable analyses revealed that body mass index (standardized coefficients of females and males (β-F/M) =143.5/102.5), serum ALT (β-F/M = 25.8/75.7), age (β-F/M = 34.3/17.2), and platelet count (β-F/M = 17.8/15.2) were positively associated with FLD in both genders. Of the 5,289 subjects free from alcohol influence, NAFLD was detected in 881 of 3,473 females (25.4%) and 921 of 1,816 males (50.7%). Body mass index (β-F/M = 113.3/55.3), serum ALT (β-F/M = 21.6/53.8), and platelet count (β-F/M = 13.8/11.8) were positively associated with NAFLD in both genders. Metabolic syndrome was positively associated with FLD and NAFLD only in males. In contrast, Helicobacter pylori infection status was neither associated with FLD nor NAFLD regardless of gender.

Conclusions

Body mass index, serum ALT and platelet count were significantly associated with FLD and NAFLD, whereas infection of Helicobacter pylori was not.

【 授权许可】

   
2015 Okushin et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Volzke H: Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? World J Gastroenterol 2012, 18(27):3492-501.
• [2]Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al.: Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997, 41(6):845-50.
• [3]Bellentani S, Bedogni G, Miglioli L, Tiribelli C: The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004, 16(11):1087-93.
• [4]DoS Alves De Carvalho M, Coelho Cabral P, Kruze Grande De Arruda I, Goretti Pessoa De Araujo Burgos M, Da Silva Diniz A, Barros Pernambuco JR, et al.: Risk factors associated with hepatic steatosis: a study in patients in the Northeast Brazil. Nutr Hosp 2012, 27(4):1344-50.
• [5]Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al.: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132(2):112-7.
• [6]Lau K, Lorbeer R, Haring R, Schmidt CO, Wallaschofski H, Nauck M, et al.: The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. J Hypertens 2010, 28(9):1829-35.
• [7]Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al.: The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatol (Baltimore, Md) 2012, 55(6):2005-23.
• [8]Sookoian S, Castano GO, Pirola CJ: Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut 2014, 63(3):530-2.
• [9]Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T: Protective effect of alcohol consumption for fatty liver but not metabolic syndrome. World J Gastroenterol 2012, 18(2):156-67.
• [10]Liangpunsakul S, Chalasani N: What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol 2012, 107(7):976-8.
• [11]Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S: Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003, 38(10):954-61.
• [12]Ryan CK, Johnson LA, Germin BI, Marcos A: One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002, 8(12):1114-1122.
• [13]Nadalin S, Malago M, Valentin-Gamazo C, Testa G, Baba HA, Liu C, et al.: Preoperative donor liver biopsy for adult living donor liver transplantation: risks and benefits. Liver Transpl 2005, 11(8):980-6.
• [14]Tran TT, Changsri C, Shackleton CR, Poordad FF, Nissen NN, Colquhoun S, Geller SA, Vierling JM, Martin P: Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol 2006, 21(2):381-383.
• [15]Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007, 47(2):239-244.
• [16]Minervini MI, Ruppert K, Fontes P, Volpes R, Vizzini G, de Vera ME, Gruttadauria S, Miraglia R, Pipitone L, Marsh JW, et al.: Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol 2009, 50(3):501-510.
• [17]Vernon G, Baranova A, Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34(3):274-285.
• [18]Baffy G, Brunt EM, Caldwell SH: Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. In Journal of hepatology. Volume 56. Published by Elsevier B.V, England; 2012:1384-91.
• [19]Rubinstein E, Lavine JE, Schwimmer JB: Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28(4):380-5.
• [20]de Alwis NM, Day CP: Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008, 48(Suppl 1):S104-12.
• [21]Machado M, Marques-Vidal P, Cortez-Pinto H: Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006, 45(4):600-606.
• [22]Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30(5):1212-1218.
• [23]Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, et al.: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37(4):917-923.
• [24]Frasinariu OE, Ceccarelli S, Alisi A, Moraru E, Nobili V: Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis 2013, 45(7):543-51.
• [25]Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al.: Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482(7384):179-85.
• [26]Solga SF, Diehl AM: Gut flora-based therapy in liver disease? The liver cares about the gut. Hepatology (Baltimore, Md) 2004, 39(5):1197-200.
• [27]Chassaing B, Etienne-Mesmin L, Gewirtz AT: Microbiota-liver axis in hepatic disease. Hepatology (Baltimore, Md) 2014, 59(1):328-39.
• [28]Cover TL, Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology 2009, 136(6):1863-73.
• [29]Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, et al.: Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012, 61(5):646-664.
• [30]Matsuhisa T, Aftab H: Observation of gastric mucosa in Bangladesh, the country with the lowest incidence of gastric cancer, and Japan, the country with the highest incidence. Helicobacter 2012, 17(5):396-401.
• [31]Takahashi Y, Yamamichi N, Shimamoto T, Mochizuki S, Fujishiro M, Takeuchi C, Sakaguchi Y, Niimi K, Ono S, Kodashima S, et al.: Helicobacter pylori infection is positively associated with gallstones: a large-scale cross-sectional study in Japan. J Gastroenterol 2014, 49(5):882-889.
• [32]Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, et al.: Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995, 311(7007):711-4.
• [33]Federman DG, Kirsner RS, Moriarty JP, Concato J: The effect of antibiotic therapy for patients infected with Helicobacter pylori who have chronic urticaria. J Am Acad Dermatol 2003, 49(5):861-4.
• [34]Maurer KJ, Ihrig MM, Rogers AB, Ng V, Bouchard G, Leonard MR, et al.: Identification of cholelithogenic enterohepatic helicobacter species and their role in murine cholesterol gallstone formation. Gastroenterology 2005, 128(4):1023-33.
• [35]Naja F, Nasreddine L, Hwalla N, Moghames P, Shoaib H, Fatfat M, et al.: Association of H. pylori infection with insulin resistance and metabolic syndrome among Lebanese adults. Helicobacter 2012, 17(6):444-51.
• [36]Cho I, Blaser MJ, Francois F, Mathew JP, Ye XY, Goldberg JD, Bini EJ: Helicobacter pylori and overweight status in the United States: data from the Third National Health and Nutrition Examination Survey. In: Am J Epidemiol. Volume 162, edn. United States; 2005: 579–584.
• [37]Longo-Mbenza B, Nkondi Nsenga J, Vangu Ngoma D: Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics. Int J Cardiol 2007, 121(3):229-238.
• [38]Polyzos SA, Kountouras J, Zavos C, Deretzi G: Helicobacter pylori Infection and insulin resistance. Helicobacter 2013, 18(2):165-6.
• [39]Stergiopoulos C, Kountouras J, Daskalopoulou-Vlachoyianni E, Polyzos SA, Zavos C, Vlachoyiannis E, Kokkali S, Deretzi G, Kapetanakis N, Katsinelos P, et al.: Helicobacter pylori may play a role in both obstructive sleep apnea and metabolic syndrome. Sleep Med 2012, 13(2):212-213.
• [40]Shin DW, Kwon HT, Kang JM, Park JH, Choi HC, Park MS, Park SM, Son KY, Cho B: Association between metabolic syndrome and Helicobacter pylori infection diagnosed by histologic status and serological status. J Clin Gastroenterol 2012, 46(10):840-845.
• [41]Pietroiusti A, Diomedi M, Silvestrini M, Cupini LM, Luzzi I, Gomez-Miguel MJ, et al.: Cytotoxin-associated gene-A–positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation 2002, 106(5):580-4.
• [42]Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A: Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol 2008, 103(12):3005-3010.
• [43]Polyzos SA, Kountouras J, Papatheodorou A, Patsiaoura K, Katsiki E, Zafeiriadou E, et al.: Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013, 62(1):121-6.
• [44]Danjo A, Yamaguchi K, Fujimoto K, Saitoh T, Inamori M, Ando T, et al.: Comparison of endoscopic findings with symptom assessment systems (FSSG and QUEST) for gastroesophageal reflux disease in Japanese centres. J Gastroenterol Hepatol 2009, 24(4):633-8.
• [45]Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, et al.: Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol 2004, 39(9):888-91.
• [46]Yamamichi N, Mochizuki S, Asada-Hirayama I, Mikami-Matsuda R, Shimamoto T, Konno-Shimizu M, et al.: Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores. BMC Med 2012, 10:45. BioMed Central Full Text
• [47]Shimamoto T, Yamamichi N, Kodashima S, Takahashi Y, Fujishiro M, Oka M, et al.: No association of coffee consumption with gastric ulcer, duodenal ulcer, reflux esophagitis, and non-erosive reflux disease: a cross-sectional study of 8,013 healthy subjects in Japan. PLoS One 2013, 8(6):e65996.
• [48]Minatsuki C, Yamamichi N, Shimamoto T, Kakimoto H, Takahashi Y, Fujishiro M, et al.: Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan. PLoS One 2013, 8(7):e69891.
• [49]Yamamichi N, Hirano C, Shimamoto T, Minatsuki C, Takahashi Y, Nakayama C, et al.: Associated factors of atrophic gastritis diagnosed by double-contrast upper gastrointestinal barium x-ray radiography: a cross-sectional study analyzing 6,901 healthy subjects in Japan. PLoS One 2014, 9(10):e111359.
• [50]Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, et al.: The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007, 102(12):2708-15.
• [51][Definition and the diagnostic standard for metabolic syndrome--Committee to Evaluate Diagnostic Standards for Metabolic Syndrome]. Nihon Naika Gakkai zasshi The Journal of the Japanese Society of Internal Medicine 2005, 94(4):794–809.
• [52]Karcz WK, Krawczykowski D, Kuesters S, Marjanovic G, Kulemann B, Grobe H, et al.: Influence of Sleeve Gastrectomy on NASH and Type 2 Diabetes Mellitus. J Obes 2011, 2011:765473.
• [53]Dowman JK, Tomlinson JW, Newsome PN: Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011, 33(5):525-40.
• [54]Inabe F, Takahashi E, Moriyama K, Negami M, Otsuka H: Risk assessment chart for predicting fatty liver in Japanese subjects. Tokai J Exp Clin Med 2012, 37(4):94-101.
• [55]Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, et al.: Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996, 23(5):1025-9.
• [56]Ludwig J, McGill DB, Lindor KD: Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997, 12(5):398-403.
• [57]Lucey MR, Mathurin P, Morgan TR: Alcoholic hepatitis. N Engl J Med 2009, 360(26):2758-69.
• [58]Altamirano J, Bataller R: Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol 2011, 8(9):491-501.
• [59]Mulhall BP, Ong JP, Younossi ZM: Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002, 17(11):1136-43.
• [60]Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 1997, 126(2):137-45.
• [61]Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al.: Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123(1):134-40.
• [62]Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, et al.: Review article: the diagnosis of non-alcoholic fatty liver disease – availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013, 37(4):392-400.
• [63]Strauss S, Gavish E, Gottlieb P, Katsnelson L: Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007, 189(6):W320-3.
• [64]Yamaji Y, Okamoto M, Yoshida H, Kawabe T, Wada R, Mitsushima T, et al.: Cholelithiasis is a risk factor for colorectal adenoma. Am J Gastroenterol 2008, 103(11):2847-52.